NanoPass Technologies has entered into a license agreement for its MicronJet delivery device with Janssen Pharmaceuticals for multiple vaccine fields. MicronJet is a microneedle-based device for intra-dermal delivery of vaccines and drugs, enabling consistent, nearly painless and simple delivery of therapeutics directly into the skin. MicronJet has proven efficacy and safety in multiple applications including flu vaccines and insulin.
The technology demonstrated in a recent phase II flu vaccine study that
“MicronJet is an enabling technology which allows to reduce the dose, improve the vaccination effect and at the same time improve patient comfort and compliance, ” says Yotam Levin, CEO.
The company is backed by Israeli and US investors including IHCV, Ofer Hi Tech, D Partners, WFD Ventures and Elcam Medical.